Background: A frequent hyperandrogenic condition brought on by increased androgen hormone production is Polycystic Ovary Syndrome. The present study was conducted to assess the role of myoinositol in the management of PCOS and obesity. Materials & Methods: 58 women from aged 18 to 30 years diagnosed with PCOS were enrolled. Parameters such as improvement in acne, reduction in hirsutism and weight loss, BMI, random sugar level and fasting insulin levels were recorded. Results: The mean pre- BMI was 27.6 and post BMI was 25.3. RBS was 116.4 and 112.7 and fasting insulin was 17.9 and 16.5 pre- operatively and post- operatively. The difference was significant (P< 0.05). Pre- operatively and post- operatively, regular menstrual cycle was seen in 55% and 78%, oligomenorrhea in 30% and in 17%, polymenorrhea in 9% and 4% and secondary amenorrhea in 6% and 1% respectively. Facial acne was seen in 92% and 54% and improved in 40%. Hirsutism was seen in 70% and 25% and improved in 44%. Ultrasound pelvis had PCO in 98% and 41% and improved in 2% and 59% respectively. The difference was significant (P< 0.05). Conclusion: Myo-inositol has been shown to be useful in lowering PCO and its associated symptoms in women.